Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study
| Autor: | M M, van Gameren, P H, Willemse, N H, Mulder, P C, Limburg, H J, Groen, E, Vellenga, E G, de Vries |
|---|---|
| Rok vydání: | 1994 |
| Předmět: |
Adult
Male Lung Neoplasms Interleukin-6 Platelet Count Immunology Breast Neoplasms Enzyme-Linked Immunosorbent Assay Cell Biology Hematology Middle Aged Biochemistry Lymphocyte Subsets Recombinant Proteins Hematopoiesis Hemoglobins Leukocyte Count Cholesterol Carcinoma Non-Small-Cell Lung Cytokines Humans Female |
| Zdroj: | Blood. 84:1434-1441 |
| ISSN: | 1528-0020 0006-4971 |
| Popis: | To define the toxicity profile of recombinant human interleukin-6 (rhIL- 6) and to study its effect on hematopoiesis, biochemical parameters and other cytokines, rhIL-6 was administered in a phase I-II study to 20 patients with breast carcinoma or nonsmall cell lung cancer. RhIL-6 doses were 0.5, 1.0, 2.5, 5.0, 10, and 20 micrograms/kg/d, with at least three patients per dose level. RhIL-6 was administered 24 hours by continuous intravenous infusion followed by subcutaneous (SC) administration for 6 days, partly on an outpatient basis. RhIL-6- related side effects were fever, headache, myalgia, and local erythema. Starting at 2.5 micrograms/kg/d, these side effects were compounded by nausea, reversible increase in liver enzymes, and anemia. Flu-like symptoms were controllable up to and including 10 micrograms rhIL- 6/kg/d with acetaminophen. RhIL-6 increased platelet counts with a decrease in mean platelet volume and increased leukocytes caused by neutrophil, monocyte, and lymphocyte increase, with an increase in T cells and natural killer cells at 1.0 and 2.5 micrograms rhIL-6/kg/d. The reversible anemia was characterized by a decrease in serum iron, and an increase in ferritin and erythropoietin without reticulocytosis. RhIL-6 reduced total cholesterol levels and a dose-related increase of C-reactive protein and serum amyloid A plasma levels was observed. Serum IL-6 levels were increased, especially at 10 and 20 micrograms/kg/d, whereas no change in IL-1 beta and tumor necrosis factor alpha levels was observed. RhIL-6 can be administered with controllable side effects in this setting, up to and including a SC dose of 10 micrograms/kg/d on an outpatient basis, and has a promising stimulating effect on leukopoiesis and thrombopoiesis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|